Voyager TherapeuticsSTU:VT6 55 FCF Margin % is -1,289.30% as of Mar. 2026. GuruFocus rates STU:VT6 with a GF Score™ of 55/100 and a GF Value™ of €1.52 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 960 Biotechnology companies, Voyager Therapeutics ranks worse than 66.98% on this metric.
The historical rank and industry rank for Voyager Therapeutics's FCF Margin % or its related term are showing as below:
STU:VT6'
s FCF Margin % Range Over the Past 10 Years
Min: -644.65 Med: -105.48 Max: 39.23
Current: -357.69
During the past 13 years, the highest FCF Margin % of Voyager Therapeutics was 39.23%. The lowest was -644.65%. And the median was -105.48%.
STU:VT6's FCF Margin % is ranked worse than 66.98% of 960
companies
in the Biotechnology industry
Industry Median: -85.21
vs STU:VT6: -357.69
Voyager Therapeutics FCF Margin % Related Terms
Voyager Therapeutics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Voyager Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:VT6 vs CRBU, OBIO, WHWK: FCF Margin % Comparison
For the Biotechnology subindustry, Voyager Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyager Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Voyager Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voyager Therapeutics (STU:VT6) has a FCF Margin % of -1,289.30% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Voyager Therapeutics and its competitors. According to the industry distribution chart, Voyager Therapeutics ranks #643 out of 960 companies in the Biotechnology industry, placing it in the top 67%.
Is Voyager Therapeutics' FCF Margin % too high?
Voyager Therapeutics' current FCF Margin % is -1,289.30%. Based on the distribution chart, Voyager Therapeutics ranks #643 out of 960 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Voyager Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' FCF Margin % compare to CRBU and OBIO?
According to the Biotechnology industry distribution chart, Voyager Therapeutics ranks #643 out of 960 companies for FCF Margin %. This places Voyager Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Voyager Therapeutics and its competitors. Voyager Therapeutics's current FCF Margin % is -1,289.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (STU:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.52, compared to a current price of €3.22 — trading 112.1% above its estimated fair value. The current FCF Margin % is -1,289.30%. Voyager Therapeutics' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Voyager Therapeutics (STU:VT6), the current FCF Margin % is -1,289.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Voyager Therapeutics (STU:VT6) Overvalued in 2026?
Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued.
The current stock price of €3.22 is trading 112.1% above its estimated GF Value™ of €1.52.
GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.
Key valuation signals for STU:VT6:
FCF Margin %: -1,289.30%
GF Value™: €1.52 vs. price of €3.22 (112.1% above fair value)
No single metric tells the full story. See the STU:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
55GF Score
Get the complete analysis for STU:VT6
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:VT6 has been successfully added to your 
